ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017
22 abstracts related to HIV treatment and prevention to be presented at major international HIV conference
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting 22 abstracts at the annual conference of the International AIDS Society (IAS) 23–26 July, 2017, Paris, France.
John C. Pottage Jr, Chief Scientific and Medical Officer at ViiV Healthcare, commented: “People living with HIV, and their healthcare providers, continue to look for improvements in areas related to their long-term care, such as tolerability, safety, dosing schedules, drug interactions and convenience. The data we’re sharing at IAS this year demonstrate our R&D focus on patient-centred care, with a clear drive to find new treatment regimens, new ways to deliver HIV treatments and entirely new molecules to treat and prevent HIV.”
While significant progress has been made in tackling the global HIV epidemic, it remains a substantial public health challenge, as 2.1 million people were newly infected in 2014 and more than 36 million people live with HIV worldwide.[i] Data to be presented at IAS support ViiV Healthcare’s commitment to delivering advances in treatment and prevention options for people living with HIV (PLHIV). Key data highlights include:
- Phase III data comparing a dolutegravir-based regimen against lopinavir/ritonavir-based regimens in patients failing first-line therapy in resource-limited settings (DAWNING)
- A sub-study of SWORD 1 & 2: effect of switching from TDF-based regimens to dolutegravir and rilpivirine on bone mineral density and bone turnover markers
- Longer-term (96-week) safety and efficacy data from a phase II study of a long-acting, two-drug regimen including cabotegravir and rilpivirine (LATTE-2)
- Safety, efficacy and effects on lipid profiles of switching from a boosted protease-inhibitor-based regimen to dolutegravir-based regimen in HIV patients with high CV risk (NEAT 022)
- Phase II data from a safety and acceptability study of long-acting, injectable, cabotegravir in HIV-uninfected men and women (HPTN 077)
- Phase II safety and efficacy data for a two-drug regimen of dolutegravir and lamivudine in treatment-naïve patients in high- and low-baseline viral load (ACTG 5353)
- Results from an international survey of PLHIV to explore the impact of living with an HIV diagnosis on quality of life, outlook and aspirations
These data cover a wide range of important areas in HIV research, such as:
- Safety and efficacy in diverse populations including treatment-naïve, treatment-experienced individuals, paediatric patients and women living with HIV who are also pregnant.
- Quantitative and qualitative research into the lives of PLHIV, and their needs and expectations.
The breadth of this research is a result of ViiV Healthcare’s holistic approach to innovation and dedication to advancing options to help lessen the lifetime burden of HIV therapy on the lives of PLHIV and to reduce the chance of infection altogether.
Accepted Abstracts
Dolutegravir
|
Abstract |
Title |
Lead Author |
Type |
Location/Time |
|
MOPEB0283 |
Dolutegravir use during pregnancy and birth outcomes: data from the Antiretroviral Pregnancy Registry (APR) |
V. Vannappagari |
Poster Exhibition |
Poster Exhibition Area Monday, 24 July |
|
MOPEC0609 |
Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir |
C. Thorne |
Poster Exhibition |
Poster Exhibition Area Monday, 24 July |
|
MOPEB0287 |
Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV-naive patients: 96 week results of the PADDLE trial |
M. I. Figueroa |
Poster Exhibition |
Poster Exhibition Area Monday 24, July |
|
TUPDB0205LB |
Sub-study 202094 of SWORD 1 & SWORD 2: switch from TDF-containing regimen to DTG+RPV improves bone mineral density and bone turnover markers over 48 weeks |
G. McComsey |
Poster Discussion Abstract |
Havana Amphitheater Tuesday, 25 July 13:00 |
|
TUAB0102 |
Switching from a boosted protease inhibitor (PI/r)-based regimen to a dolutegravir regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years is non-inferior and decreases lipids |
J. M. Gatell |
Oral Abstract |
Le Grand Amphithéâtre Tuesday 25, July 14:45 |
|
TUAB0105LB |
Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study |
M. Aboud |
Oral Abstract |
Le Grand Amphithéâtre Tuesday 25, July 15:45 |
|
MOAB0103 |
ACTG A5353: a pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/mL |
B. O. Taiwo |
Oral Abstract |
Le Grand Amphithéâtre Monday, 24 July 11:30 |
|
WEPEB0573 |
Initial regimen duration in female patients taking integrase strand transfer inhibitors (INSTI) in the OPERA® observational database |
F. Carpio |
Poster Exhibition |
Poster Exhibition Area Wednesday, 26 July |
Cabotegravir
|
Abstract |
Title |
Lead Author |
Type |
Location/Time |
|
MOAX0205LB |
Safety and efficacy of long-acting CAB and RPV as two-drug IM maintenance therapy: LATTE-2 week 96 results |
J. Eron |
Oral Abstract |
Blue Amphitheater Monday, 24 July 12:00 |
|
TUAC0106LB
|
Safety, tolerability and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected women and men: HPTN 077 |
R. Landovitz |
Oral Abstract |
Blue Amphitheater Tuesday, 25 July 12:15 |
Fostemsavir
|
Abstract |
Title |
Lead Author |
Type |
Location/Time |
|
MOPEB0339 |
The effect of fostemsavir on the pharmacokinetics of a combined oral contraceptive (OC) containing ethinyl estradiol (EE) and norethindrone (NE) in healthy female subjects |
M. Magee |
Poster Exhibition |
Poster Exhibition Area Monday, 24 July |
|
MOPEB0338 |
The effect of fostemsavir on methadone and buprenorphine pharmacokinetics |
H. Sevinsky |
Poster Exhibition |
Poster Exhibition Area Monday, 24 July |
Abacavir
|
Abstract |
Title |
Lead Author |
Type |
Location/Time |
|
WEPEB0542 |
Uptake of HLA-B*5701 screening and its impact on clinically suspected hypersensitivity reaction to abacavir in the OPERA® Observational Database |
K. Mounzer |
Poster Exhibition |
Poster Exhibition Area Wednesday, 26 July |
Maraviroc
|
Abstract |
Title |
Lead Author |
Type |
Location/Time |
|
TUPEB0435 |
Longer-term safety of maraviroc in paediatric patients with R5 HIV: follow-up data from study A4001031 |
C. Giaquinto |
Poster Exhibition |
Poster Exhibition Area Tuesday, 25 July |
|
TUPEB0433 |
Maraviroc pharmacokinetics and dosing recommendations in CCR5-tropic HIV-1-infected children aged 2 to <18 years |
M. Vourvahis |
Poster Exhibition |
Poster Exhibition Area Tuesday, 25 July |
|
TUPEB0432 |
Pharmacokinetic (PK) modelling and simulation to support weight-based dosing of maraviroc (MVC) in paediatric subjects when co-administered with potent CYP3A inhibitors |
L. McFadyen |
Poster Exhibition |
Poster Exhibition Area Tuesday, 25 July |
GSK3532795/BMS-955176
|
Abstract |
Title |
Lead Author |
Type |
Location /Time |
|
MOPEB0347 |
Resistance profile of GSK3532795 |
I. Dicker |
Poster Exhibition |
Poster Exhibition Area Monday, 24 July |
|
TULBPEB21
|
Safety, efficacy, and dose-response of GSK3532795/BMS-955176 plus tenofovir/emtricitabine (TDF/FTC) in treatment-naïve (TN) HIV-1-infected adults: week 24 primary analysis |
J. Morales-Ramirez |
Poster Exhibition |
Poster Exhibition Area Tuesday, 25 July |
|
WEPEB0540 |
An analysis of neurologic and psychiatric adverse events of subjects receiving the investigational HIV-1 maturation inhibitor (MI) GSK3532795/BMS-955176 |
J. Gan |
Poster Exhibition |
Poster Exhibition Area Wednesday, 26 July |
Other/Non-Product Related
|
Abstract |
Title |
Lead Author |
Type |
Location/Time |
|
MOPEB0274 |
Atypical mutations for RAL resistant clinical isolates, and associated integrase strand transfer inhibitor susceptibility with public algorithms |
M. Underwood |
Poster Exhibition |
Poster Exhibition Area Monday, 24 July |
|
WEPED1423 |
Experience of living with HIV: diagnosis & disclosure - findings from the Positive Perspectives study |
A. Murungi |
Poster Exhibition |
Poster Exhibition Area Monday, 24 July |
|
WEAA0203 |
Inhibiting memory CD4+ T-cell self-renewal to reduce HIV persistence |
M. Mavigner |
Oral Abstract |
Maillot Room Wednesday, 26 July 17:00 |
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com/about-us.
[i] UNAIDS. Fact Sheet. Available at: http://www.unaids.org/en/resources/fact-sheet Last accessed July 2017
